Summary
Single oral doses of 10 mg converting enzyme inhibitor benazepril (CGS 14824A) and 40 mg furosemide were administered to 12 healthy male volunteers either separately or concomitantly. The pharmacokinetic parameters of benazepril were not influenced by coadministration of furosemide. Urinary excretion of total furosemide was significantly reduced by 10 to 20% in the presence of benazepril. This effect was considered clinically insignificant. Erect blood pressure decreased and pulse rate increased only during concomitant treatment.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Andreasen F, Christensen CK, Jacobsen FK, Mogensen CE (1981) The use of HPLC to elucidate the metabolism and urinary excretion of furosemide and its metabolic products. Acta Pharmacol Toxicol 49: 223–229
Fluehler H, Hirtz J, Moser HA (1981) An aid to decision-making in bioequivalence assessment. J Pharmacokinet Biopharm 9: 235–243
Griffing GT, Sindler BH, Aurecchia SA, Melby JC (1983) Reversal of diuretic-induced secondary hyperaldosteronism and hypokalaemia by enalapril (MK-421): A new angiotensin-converting enzyme inhibitor. Metabolism 32: 711–716
Grahnen A, Hammarlund M, Lundquist T (1984) Implications of intraindividual variability in bioavailability studies of furosemide. Eur J Clin Pharmacol 27: 595–602
Kaiser G, Ackermann R, Dieterle W, Dubois J-P (1987) Determination of a new angiotensin converting enzyme inhibitor and its active metabolite in plasma and urine by gas chromatography-mass spectrometry. J Chromatogr 419: 123–133
Lewis RA, Baker KM, Ayers CR, Weaver BA, Lehman MR (1985) Captopril versus enalapril maleate: A comparison of antihypertensive and hormonal effects. J Cardiovasc Pharmacol 7: S12-S15
Mandallaz D, Mau J (1981) Comparison of different methods for decision-making in bioequivalence assessment. Biometrics 37: 213–222
Rakhit A, Kochak GM, Tipnis V, Hurley ME (1987) Inhibition of renal clearance of furosemide by pentopril, an angiotensin-converting enzyme inhibitor. Clin Pharmacol Ther 41: 580–586
Schaller MD, Nussberger J, Waeber B, Bussien JP, Turini GA, Brunner H, Brunner HR (1985) Haemodynamic and pharmacological effects of the converting enzyme inhibitor CGS 14824A in normal volunteers. Eur J Clin Pharmacol 28: 267–272
Swezey SE, Meffin PJ, Blaschke TF (1979) Measurement of furosemide by high performance liquid chromatography. J Chromatogr 174: 469–473
Van Hecken AM, Verbesselt R, Buntinx A, Cirillo VJ, De Schepper PJ (1987) Absence of a pharmacokinetic interaction between enalapril and frusemide. Br J Clin Pharmacol 23: 84–87
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
De Lepeleire, I., Van Hecken, A., Verbesselt, R. et al. Interaction between furosemide and the converting enzyme inhibitor benazepril in healthy volunteers. Eur J Clin Pharmacol 34, 465–468 (1988). https://doi.org/10.1007/BF01046703
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01046703